NR1H4 and metabolic dysfunction-associated steatohepatitis: Indeed, homozygous loss of human FXR function causes severe progressive familial intrahepatic cholestasis (46), and activation of FXR by OCA treatment protects against hepatic inflammation and fibrosis in rodent models of cholestasis, cirrhosis, and NASH (3, 4, 18).